Ultragenyx Reports 2025 Revenue of $672M-$674M, Exceeding Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Source: Globenewswire
- Significant Revenue Growth: Ultragenyx's preliminary 2025 revenue is projected to be between $672 million and $674 million, exceeding the top end of guidance and representing approximately 20% growth from 2024, indicating strong market demand in the rare disease treatment sector.
- Strong Cash Position: As of December 31, 2025, the company reported approximately $735 million in cash and investments, providing a solid financial foundation for future R&D and market expansion, thereby enhancing investor confidence.
- Clinical Trial Advancements: Anticipated 2026 catalysts include two potential gene therapy approvals and pivotal Phase 3 data from the GTX-102 study, which will lay the groundwork for future growth and further solidify the company's leadership in the rare disease space.
- Forward-Looking Strategic Planning: Ultragenyx plans to issue financial guidance for 2026, including cost reduction measures, reflecting the company's focus on optimizing operational efficiency and enhancing profitability to address market competition and meet patient needs.
Analyst Views on RARE
Wall Street analysts forecast RARE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RARE is 61.65 USD with a low forecast of 35.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 24.310
Low
35.00
Averages
61.65
High
120.00
Current: 24.310
Low
35.00
Averages
61.65
High
120.00
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
